Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103814 · ClinicalTrials.gov registry record · Phase 2
Effect of Topical CBD Cream for Degenerative Hallux Disorders
A Phase 2 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04103814 is a Phase 2 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT04103814, a Phase 2 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Hallux rigidus and hallux valgus are chronic forefoot conditions associated with pain, inflammation and functional impairment. Topical cannabidiol (CBD) cream has been shown to decrease inflammation, swelling, and pain response in arthritis models with minimal side effects, although the intervention has never been studied in hallux valgus or hallux rigidus. The purpose of this study is to determine if topical CBD cream is an effective treatment for pain secondary to hallux rigidus and hallux valgus.
Interventions
- DRUG Placebo cream
- DRUG magnesium-cannabidiolic acid cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-10-20 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04103814
The ClinicalTrials.gov registry entry for NCT04103814 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo cream is the first listed.
NCT04103814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04103814 about?
NCT04103814 is a clinical study titled "Effect of Topical CBD Cream for Degenerative Hallux Disorders". Hallux rigidus and hallux valgus are chronic forefoot conditions associated with pain, inflammation and functional impairment. Topical cannabidiol (CBD) cream has been shown to decrease inflammation, swelling, and pain response in arthritis models with minimal side effects, although the intervention...
What is the current status of trial NCT04103814?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2019-10-20. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT04103814?
The interventions under investigation include: Placebo cream (DRUG), magnesium-cannabidiolic acid cream (DRUG).
Who is sponsoring clinical trial NCT04103814?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.